Collaborating to Improve Blood Cancer Treatment
Since the early 1990s, Genentech has collaborated with Biogen on CD20 technology, which led to the first monoclonal antibody to treat cancer and, in 1997, the first new treatment in a decade for non-Hodgkin’s lymphoma (NHL). This antibody has since become a foundation for treating blood cancers involving malignant B cells.
→
← Previous Year →
2016
Collaborating to Improve Blood Cancer Treatment
Read more →
Since the early 1990s, Genentech has collaborated with Biogen on CD20 technology, which led to the first monoclonal antibody to treat cancer and, in 1997, the first new treatment in a decade for non-Hodgkin’s lymphoma (NHL). This antibody has since become a foundation for treating blood cancers involving malignant B cells.
1994
Inventing “Knobs-Into-Holes” Technology for Bispecifics
Read more →
Genentech pioneered a unique “knobs-into-holes” technology that overcame manufacturing hurdles and engaged separate molecular targets. With this innovation, the company created a portfolio of bispecific antibodies that offer a combination of precision, stability and diverse targeting ability and have the potential to revolutionize the treatment of certain types of NHL.
1996
Advancing the Science of Antibody-Drug Conjugates
In the early 2000s, Genentech expanded its collaboration with Seagen and engineered an adaptable system that allowed for the mixing and matching of monoclonal antibodies and linkers to develop stable and effective antibody-drug conjugates (ADCs), novel medicines that deliver chemotherapy directly to cancerous cells.
2008
Read more →
Restoring Apoptosis Through the Power of Partnership
Read more →
In 2016, in partnership with AbbVie, Genentech launched the first B-cell lymphoma-2 inhibitor to improve outcomes for people with leukemia and lymphoma.
2016
Leveraging the Immune System in a New Way
Read more →
In 2019, Genentech began a partnership with Xencor to develop a novel IL-15 cytokine therapeutic. This molecule is designed to stimulate the expansion and activation of natural killer cells and cytotoxic T cells – a potential new way to leverage the immune system to target cancer.
2019
←
2022
2019
2016
2008
1996
1994
Exploring Allogeneic CAR-T Cell Therapy
Read more →
In 2022, Roche entered into a strategic collaboration with Poseida Therapeutics focused on allogeneic CAR-T cell therapies for blood cancers to address the limitations of first-generation cell therapies and potentially offer increased outpatient access.
Leveraging the Immune System in a New Way
Read more →
In 2019, Genentech began a partnership with Xencor to develop a novel IL-15 cytokine therapeutic. This molecule is designed to stimulate the expansion and activation of natural killer cells and cytotoxic T cells – a potential new way to leverage the immune system to target cancer.
Restoring Apoptosis Through the Power of Partnership
Read more →
In 2016, in partnership with AbbVie, Genentech launched the first B-cell lymphoma-2 inhibitor to improve outcomes for people with leukemia and lymphoma.
Advancing the Science of Antibody-Drug Conjugates
Read more →
In the early 2000s, Genentech expanded its collaboration with Seagen and engineered an adaptable system that allowed for the mixing and matching of monoclonal antibodies and linkers to develop stable and effective antibody-drug conjugates (ADCs), novel medicines that deliver chemotherapy directly to cancerous cells.
Inventing “Knobs-Into-Holes” Technology for Bispecifics
Read more →
Genentech pioneered a unique “knobs-into-holes” technology that overcame manufacturing hurdles and engaged separate molecular targets. With this innovation, the company created a portfolio of bispecific antibodies that offer a combination of precision, stability, and diverse targeting ability and have the potential to revolutionize the treatment of certain types of NHL.
Collaborating to Improve Blood Cancer Treatment
Read more →
Since the early 1990s, Genentech has collaborated with Biogen on CD20 technology, which led to the first monoclonal antibody to treat cancer and, in 1997, the first new treatment in a decade for non-Hodgkin’s lymphoma (NHL). This antibody has since become a foundation for treating blood cancers involving malignant B cells.
←
→